Domov › Uroteliálny (prechodnobunkový) karcinóm › Tennessee › Nashville
Klinické štúdie Uroteliálny (prechodnobunkový) karcinóm v meste Nashville, TN
23 štúdií pre Uroteliálny (prechodnobunkový) karcinóm hľadá účastníkov v zariadeniach v meste Nashville a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Prebieha náborFáza 1
- Tennessee Oncology, Nashville
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Prebieha náborFáza 1
- Exelixis Clinical Site #3, Nashville
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Prebieha náborFáza 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Prebieha náborFáza 2
- Vanderbilt University/Ingram Cancer Center, Nashville
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Prebieha náborFáza 3
- SCRI Oncology Partners, Nashville
DBC-664 in Adult Patients With Solid Tumors
Prebieha náborFáza 1
- SCRI Oncology Partners, Nashville
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Prebieha náborObservačná štúdia
- Vanderbilt University Medical Center, Nashville
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Prebieha náborFáza 1/2
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology, Nashville
- a 9 ďalších
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Prebieha náborFáza 1
- Sarah Cannon Research Institute, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Prebieha náborFáza 1/2
- Vanderbilt University Medical Center, Nashville
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Prebieha náborFáza 3
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Prebieha náborFáza 2/3
- Research Site, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Prebieha náborFáza 1
- Sarah Cannon Research Institute, Nashville
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Prebieha náborFáza 1/2
- Tennessee Oncology, Nashville
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Prebieha náborFáza 2/3
- Research Site, Nashville
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Prebieha náborFáza 1
- Vanderbilt- Ingram Cancer Center, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Prebieha náborFáza 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Prebieha náborFáza 1/2
- SCRI Oncology Partners, Nashville
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Prebieha náborFáza 3
- Research Site, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Prebieha náborFáza 2
- SCRI Oncology Partners, Nashville
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Prebieha nábor
- Vanderbilt University Medical Center, Nashville
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Prebieha náborFáza 2
- Site 02-007 - Urology Associates, P. C, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Prebieha náborObservačná štúdia
- Massive Bio SYNERGY-AI site, Nashville
Štúdie Uroteliálny (prechodnobunkový) karcinóm v iných mestách
- New York City, NY22 štúdií
- Houston, TX19 štúdií
- Dallas, TX18 štúdií
- Edison, NJ18 štúdií
- Los Angeles, CA17 štúdií
- Queens, NY15 štúdií
- Chicago, IL14 štúdií
- Arlington, VA12 štúdií
- Boston, MA11 štúdií
- San Antonio, TX11 štúdií
- Austin, TX10 štúdií
- Orange, CA10 štúdií
Iné štúdie v Nashville
- Nemalobunkový karcinóm pľúc97 štúdií
- Rakovina prsníka81 štúdií
- Metastatická rakovina70 štúdií
- Kolorektálny karcinóm69 štúdií
- Rakovina (všetky typy)65 štúdií
- Rakovina vaječníkov49 štúdií
- Rakovina prostaty43 štúdií
- Rakovina pľúc40 štúdií
- Skvamóznocelulárny karcinóm hlavy a krku39 štúdií
- Rakovina pankreasu39 štúdií
- Rakovina endometria38 štúdií
- Melanóm33 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.